Genprex

Leadership team

Mr. John Rodney Varner (Co-Founder, Chairman, Pres & CEO)

Mr. Ryan M. Confer M.S. (Chief Financial Officer)

Ms. Catherine M. Vaczy Esq. (Exec. VP, Gen. Counsel, Corp. Sec. & Chief Strategy Officer)

Products/ Services

Biopharma, Biotechnology, Pharmaceutical

Headquarters

Austin, Texas, United States

Established

2009

Company Registration

SEC CIK number: 0001595248

Social Media

URL

https://www.genprex.com

Overview

Location

Recognition and Award

References

Summary

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

History

Genprex was initially founded in August 2015 and is headquartered in Austin, Texas. Genprex works closely with the Institute for Biomedical Research of Barcelona and the Translational Genomics Research Institute (TGen) of Phoenix, Arizona. Genprex focus is to develop revolutionary therapies that bridge the gap between existing treatments and the optimal outcome desired.

Mission

At Genprex, we are on a mission to develop and deliver innovative gene therapies that address the needs of those afflicted with serious diseases like cancer, while delivering effective and safe treatments.

Vision

At Genprex, our vision is to become a global leader in the development and delivery of gene therapies and curative solutions for a wide range of serious diseases.

Key Team

Dr. Hemant Kumar C.P.M., EMBA, Ph.D. (Chief Manufacturing & Technology Officer)

Ms. Kalyn Dabbs (Sr. Mang. of Communications & Marketing)

Mr. Thomas C. Gallagher Esq. (Sr. VP of Intellectual Property & Licensing)

Mr. David M. Schloss (Sr. VP of HR)

Dr. William E. Gannon Jr. (Member of Clinical Advisory Board & VP of Regulatory Affairs)

Dr. Mark S. Berger M.D. (Chief Medical Officer)

Mr. Greg Jancarik C.M.A., CPA, M.B.A. (Corp. Controller)

Recognition and Awards

In 2018, Genprex’s innovative platform technology was awarded the Grand Prize of “breakthrough of the year” from the Association of American Cancer Institutes. This award recognized the company’s breakthrough technology, which is capable of delivering gene-based therapies directly to the target cells it is intended for, with potentially fewer side effects.